 TORONTO, ON ACCESSWIRE March 9, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the companys drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis ACD, a potentially debilitating condition and occupational illness. Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesas EB01 topical treatment or a placebo cream. 